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What Is The Cell Free DNA?
• double-stranded nucleic acid fragments         
• Inter blood stream during apoptosis or necrosis
• Cleaned up by macrophages
• is called ctDNA if originates from a tumor clone
• around 170 bases in length
• half-life of about two hours[1]
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What Is The Cell Free DNA?
• can be further subcategorized to:
circulating mitochondrial DNA (mtDNA)
• Circulating nuclear DNA(nDNA)[20]
• lower molecular weight than genomic DNA
5
1999   2008  2013
pancreatic cancer use of MPS for NIPT               CPM  as discordant  
1948 KRAS mutation        2003-2004 of fetal aneuploidies NIPT results     
cfDNA detected Plasenta as major          
in blood                                       sourse of cfDNA
1997                                                                                            2010
Identification of 2002 ctDNA AS potential
Male cfDNA Discovery of methylated                                        liquid biopsy                                        2016- 2018 
In mathernal serum cfDNA regions 2004-2005 2012 new
cf DNA in preeclamps potential liquid biopsy thechnology
cf6
Scientific investigation                                       clinical integration
Historical Developement
Retrieved from www.ncbi.nlm.nih.gov/pupmed
Number of pubmed publication
What Is The Cell Free DNA?
Cf DNA detected in:
• Liquid biopsy
I. Plasma
II. Blood
III. Urea
IV. Cerebrospinal fluid
V. Peritoneal fluid
VI. Fetal 
Solid biopsy
I. Solid tumor 8
What Is The Cell Free DNA?
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fast and easy
not cover all the physiological cfDNA concentration range
ranges of  the analysed samples close to LOD of those kits
small intensity response
low reliability
few commercial kits are available[24]
liquid biopsy
cfDNA In Plasma
• Drive from hematopoietic cells.
• Is fragmented by plasma nucleases
• Is realeased into plasma from tumor cells and can be
detected there
• Depending on individual health and/or therapy status [2]
• in maternal plasma is a reflection of placental health and
disease[3]
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What is the cell free DNA?
I    .Plasma
Professor Roise Redfield
The University of British 
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cfDNA IN BLOOD
• is a less invasive.
• are easy to obtain.[4]
• Normal concentration of cf DNA in healthy individuals varies from 0 to
100 ng/mL of blood, on average 30 ng/mL[14]
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cfDNA in Blood
www.sec.gov 9
cfDNA in urea(ucfDNA)
• ultra-noninvasive sample over tissue and blood.
• Compared with blood, less is known about the its role
• tool for cancer screening, diagnosis, prognosis,
• monitoring of cancer progression and therapeutic effect[5]
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cfDNA in cerebrospinal fluid
• reflected response to treatment or progressive disease 
• serve as a diagnostic especially tumor drived cfDNA
• complemnts MRI and more sensitive than conventional cytology.[17]
• Using dig pcr for detect and NGS
• After emotional stress (ES) in brain tissue could be detected
• fetal cfDNA was found in the CSF of pregnant women[29]
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cf DNA IN Peritoneal fluid
• is present in the overnight peritoneal effluent of stable CAPD 
patients.
• role in the diagnosis and prognosis of therapy‐related peritoneal 
membrane degeneration.[16]
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Fetal cf DNA
• potential markers for NIPT
• placental condition in pregnancy
• Realese into mother blood
• Undergoing apoptosis[32]
• Requires only sample from the mother
Revealed maternal metastatic disease, maternal mosaicism, placental 
mosaicism
adopted into clinical practice, due to positive insurance coverage[25]
18
clinical application 
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Raghu Aarthy(2015) Role of Circulating Cell-Free DNA in Cancers
Clinical Application
I. Cancer
• Used as a diagnoprognostic or predictive biomarker
• Provides valuable insights in tumor biologystic,.
• for developing new cancer-specific targets.
• clinical utility during and after treatment(ctDNA concentrations correlate with 
tumor size)[6]
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Clinical Application
I. Cancer
• enables new strategies for personalized cancer medicine[7]
• ucfDNA genetic alterations are mostly evaluated for urological cancers[8]
• Breast cancer metastasis suppressor-1promoter methylation in cf DNA 
isolated from plasma of non-small cell lung cancer patients  provides 
prognostic information[12]
• cfDNA stimulate hormone receptor-positive breast cancer cell proliferation
by activating the TLR9-NF-κB-cyclin D1 pathway
• concentration correlated positively with the percent of cells in the G1 
phase[13]
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Clinical Application
• I.CANCER
Tian Lu.(2017) Clinical applications of urinary cell-free DNA in cancer: current insights 
and promising future.
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Clinical Application
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Raghu Aarthy(2015) Role of Circulating Cell-Free DNA in Cancers
Clinical Application
II.Spontaneous Abortion
• potential markers for noninvasive monitoring during
the pregnancy[9] 
• increased in with  spontaneous preterm birth.[10]
• FF cfDNA level was an independent and predictive factor for 
pregnancy outcome.[11]
• can be detected Chromosomal anomalies[12]
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Clinical Application                   
II. Spontaneous Abortion
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Clinical Application
III.Forensic
• Cf DNA of a suitable length for standard DNA profiling are transferred 
during handling/touching[26]
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1ML cf sweat   11.5 ng DNA
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Clinical Application
 Autoimmune disease
 SLE
• DNA structures that are targeted by auto-antibodies play a
central role in SLE and that DNA-antibody complexes in the circulation
are one of the hallmarks of SLE[14]
• it prove to be relevant to diagnostic and assessment of therapy[15]
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Clinical application
Myocardial infraction
• associated with the apoptosis and death of cardiomyocytes.
• is released following programmed cell death or acute cellular injury.
• detected in plasma from patients.[18]
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Clinical application
Trauma
• correlates inversely to mortality, trauma severity, and post-traumatic 
complications.
• has received increasing attention in ICU patient as a result of truma.
• a marker of the patient’s condition in the immediate emergency phase 
due to short half-life. [21]
• the innate immune response following aseptic injury.
• the systemic inflammatory response observed following trauma.
•
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Clinical application
Trauma
may also give rise to coagulopathy by:
platelet aggregation
inhibition of fibrinolysis
coagulation factor activation[22]
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Quantification of cfDNA
32Raghu Aarthy(2015) Role of Circulating Cell-Free DNA in Cancers
Quantification of cfDNA
• 32P-labeled radioimmunoassays.
• Spectrophotometric determination
• Invitrogen’s Qubit® quantitation fluorometer highly accurate and sensitive 
detection
• commercial fluorescent SYBR® Gold stain
• Fluorometric PCR assay[7]
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Quantification of cfDNA
MASS-Spectrometry
• MALDI-TOF MASS Spectrometry
• ESI-Mass spectrometry
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Quantification and analysis  of cf DNA
PCR
• Alu-based real time PCR
• Alu reduplicative elements
• signal amplification using fluorescence quantification.
• reliable, accurate and sensitive.
• normal control cfDNA <MI group 
• ALU4 and ALU5 showed better sensitivity and
compared with cTnI ,CK-MB,LDH 
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Alu-based real time PCR
• Alu sequences account for >10% of the genome and are abundant in 
blood 
• Therefore, a potentially sensitive approach for the
measurement of human cfDNA in blood.
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Alu-based real-time PCR
ROC
to evaluate the predictive value
of Alu-based real-time  PCR[18]
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Quantification of cfDNA
MALDI-TOF MASS Spectrometry
• accurate and sensitive high-throughput clinical diagnostic tests.
• precise determination of fetal SNP.
• noninvasive detection of fetal point mutations for  βthalassemia.[19]
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Quantification of cfDNA
ESI-Mass spectrometry
For example in HCC:
• sensitive for identification of mutations
• HPLC-ESI-MS-SOMA protocol used for screening 
• SOMA assay combines:
PCR amplification
restriction digestion
Electrospray ionization mass spectrometry[7] 39
technical advances 
• new assay :
low concentration range, around the LOD
signal amplification strategies:
 antibody conjugates
enzymatic amplification
sophisticate equipmen
• overcomes the limitations of the commercial kits
• without complex designs
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technical advances 
• NGS
• Sequensing TM
• Nanothechnology:
A plasmonic nanosensor with  inverse sensitivity
A Versatile Nanowire Platform
electroactive conducting polymer  nanowire platforms
• The value fluorimetry and spectrophotometry(nanodrop)
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Next generation sequensing
• comprehensive of genomic targets from a single sample
• it obviates the need for repeat invasive tissue biopsies[27]
• Very high ability
• Massively parallel
• Cost lower than sanger sequensing
• chromosomal and microdeletion disorders through maternal blood screening.
• Prenatal genetic carrier screening
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Next generation sequensing
Disadvantage
• a lot of raw information      
• the analysis and interpretation new variant is difficult
• Expensive equipment[28]
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Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate 
Evaluation of Cell-Free Circulating Tumor DNA(2015)
SequensingTM
• high-quality sequencing of circulating tumor DNA
• over 50 cancer-related genes with a simple blood test
• reduction in the costs, complications 
• invasive tissue biopsies for genomic testing
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A plasmonic nanosensor with  inverse 
sensitivity
• inverse sensitivity
• CTAB coated AuNRs
• interact with dsDNA
concentration-dependent AuNR aggregation
UV-Vis spectroscopy
Fast and easy to use
not involve enzymes
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A plasmonic nanosensor with  inverse 
sensitivity
• Simpler
• few experimental times
• few multi-step proceduces[24]
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A Versatile Nanowire Platform 
• Detection HPV
• minimal amounts of urine samples
• PEI-mPpy NWs 
• extraction, identification, and PCR-free colorimetric detection
• cost-effective 
• high sensitivity and accuracy
• nanowire-DNA complexes
• Inexpensive[30]
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A Versatile Nanowire Platform 
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A Versatile Nanowire Platform 
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A Versatile Nanowire Platform 
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electroactive conducting polymer 
nanowire platforms
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efficient strategies 
TUMOR BIOLOGY
new cancer-specific 
targets
Use of electroactive conducting polymer 
nanowire platforms
• the efficient capture and release
• plasma samples from patients with breast and lung cancers.
• at high yield and purity
• simple, fast, and reliable
• accurate diagnostic and prognostic information
• yielding improved outcomes for cancer patients
• interactions between Ppy/Au NWs and DNA with pico green
fluorescence[31]
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